Enveric Biosciences, Inc. · NASDAQ:ENVB

Enveric Biosciences — Investor Presentation (March 2022)

19 slides from Enveric Biosciences's investor presentation, March 2022

  1. Slide 1: Investor Deck March 2022

    Investor Deck March 2022 NASDAQ: ENVB

  2. Slide 2: Disclaimer

    Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu

  3. Slide 3: A platform of next generation psychedelic and cannabinoid medicines

    A platform of next generation psychedelic and cannabinoid medicines We leverage our discovery engine and intellectual property portfolio to create next-generation psychedelics and cannabinoids for the mind and body, with lead products in Cancer. 3

  4. Slide 4: Executing with Experience and Passion: Pharma & Biotech Leadership

    Executing with Experience and Passion: Pharma & Biotech Leadership Management Team Board of Directors Dr. Joseph Tucker Mr. Avani Kanubaddi David Johnson Dr. Joseph Tucker Chief Executive Officer & President & Chief Operating Officer Executive Chairman Chief Executive Officer & Director Director For

  5. Slide 5: Execute on Clinical Assets and Invest in Discovery Assets

    Execute on Clinical Assets and Invest in Discovery Assets Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Major Next Steps Timing EV101* GBM Phase 1 Q2 2022 EV102 RD IND Submission Q4 2022 EVM101 CRD IND Submission Q3 2022 EVM201 CRD Candidate Nomination Q2 2022 * Evaluating strategic alter

  6. Slide 6: The Platform – Next Generation Medicines

    The Platform – Next Generation Medicines Psychedelics MIND Hallucinogenic · Non-Hallucinogenic $70+ Cancer Related Distress $20+B1,2,3 BILLION BODY Depression $12+ B1 PTSD $990+ M2 Anxiety $7+ B3 Market $140+ Substance Abuse $31+ B4 Opportunity BILLION Psychedelics Cannabinoids Non-Hallucinogenic Ca

  7. Slide 7: Psychedelics – Addressing the Mind

    Psychedelics – Addressing the Mind 7

  8. Slide 8: Psychedelics: Market and Investor Validation

    Psychedelics: Market and Investor Validation Market Validation • J&J Spravato first • FDA Breakthrough • Bio-pharma and Life Science approved Psychedelic Status for 2 Drugs Institutional Investors are putting money to work in a • $3B Estimated Peak • MDMA meaningful way in Revenue Psychedelics • Psi

  9. Slide 9: Psybrary allows us to potentially expand market exponentially

    Psybrary allows us to potentially expand market exponentially Current Therapist-delivery model limits the Patient Population Served Gen 1 & 2 Psychedelic Model Psychotherapy with Psychedelics Gen 3 - NCE Model 9

  10. Slide 10: Industry Landscape: Rapidly Evolving Sector

    Industry Landscape: Rapidly Evolving Sector Company Type Indication Drug Gen 1/2/3 Market Cap DemeRx NASDAQ: ATAI Opioid Use Disorder DMX-NB1 Noribogaine Gen 1 $836MM Psiliocybin Compass NASDAQ: CMPS Treatment Resistant Depression Gen 1 $510MM COMP360 MindMed NASDAQ: MNMD Multiple LSD, MDMA, Mescali

  11. Slide 11: Psybrary – Engine for Next Generation Molecules

    Psybrary – Engine for Next Generation Molecules 11

  12. Slide 12: Psybrary offers Massive Diversity Enabling Generation 2 & 3 Drugs

    Psybrary offers Massive Diversity Enabling Generation 2 & 3 Drugs Broad Intellectual Property Coverage Derivative Molecules Classic Molecule Patent Filings Protected Psilocybin & 10 Filed Patents 1 Million+ DMT Mescaline/ 1 Million+ 4 Filed Patents MDMA Possible (1) (1) These figures represent the C

  13. Slide 13: PsyAI – Organizing and Analyzing the vast Psybrary

    PsyAITM – Organizing and Analyzing the vast Psybrary 13

  14. Slide 14: $20B+ Global Market Opportunity

    Cancer Related Distress (CRD): Opportunity to Improve High Unmet Need Current Problem Scientific Hypothesis Enveric Solution Path Gen 1 candidate • File IND Q3 • 71% cancer patients with mental • Scientific Evidence: psychedelics • Begin clinical trial Q4 2022 health challenges, 40% with impacting m

  15. Slide 15: Cannabinoids – Addressing the Body

    Cannabinoids – Addressing the Body 15

  16. Slide 16: Radiation Dermatitis (RD): $1B Opportunity to Improve High Unmet Need

    Radiation Dermatitis(RD): $1B Opportunity to Improve High Unmet Need Current Problem Scientific Hypothesis Enveric Solution Path • 50% cancer patients  radiation • Scientific Evidence: cannabinoids • Enveric novel formulation for RD impacting inflammation • IND Filing Q4 2022 • Radiation Dermatitis

  17. Slide 17: :ENVB

    :ENVB Cash and Cash equivalents as of December 31, 2021 • Cash On-hand - $17.4 million (additional $10M raise in Feb. 2022) • Debt - Zero Capital Raise • Jan 2021: $9.5 million • Feb 2021: $12.1 million • Warrant exercise (Mar 2021): $3.3 million • Feb 2022: $10 million Issued Shares • Outstanding s

  18. Slide 18: Expected Catalysts and Milestones

    Expected Catalysts and Milestones 2021 2022 EVM201: CRD EVM301: CRD EV102: RD EVM201: CRD EV102: RD EV101: GBM EVM301: CRD • Complete Hit • Complete Target • Murine Model • Lead Candidate • Complete • Start Phase I/II • Complete Virtual Generation Identification Study Results Nomination preclinical

  19. Slide 19: Building a Discovery & Clinical Platform to Serve the Mind and Body

    BUILDING A DISCOVERY & CLINICAL PLATFORM TO SERVE THE MIND AND BODY INVESTOR PRESENTATION (NASDAQ: ENVB) For more information please contact: ir@enveric.com 19

Enveric Biosciences — Investor Presentation (March 2022) on 6ix